INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
07/21/2026
Back to search
Official data from USPTO
MELAGENIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
07/21/2026
Trademark type
Combined
Nice classes
42, 44
Filing date
03/09/2018
Registration date
05/07/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/21/2025
Last transaction
07/21/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
5
Owner type
16
Owner location
DE
Examiner
RIEPEL, CHRISTINA MAXINE
Law office
N60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "MELAGENIX", "MELA" in black and "GENIX" in blue.
Holders and representatives
Holders
NeraCare GmbH
Representatives
Samantha N. Skains-Menchaca Bradley Arant Boult Cummings LLP
Technical classification
Nice Classes
Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Chemical laboratories; scientific laboratory services; analytical laboratory serviceslaboratory analysis in the field of dermatologygene technology and skin cancer
Class 44
Medical laboratory services for the analysis of samples taken from patients; medical diagnostic servicesmedical testing for diagnostic or treatment purposes; medical information; medical advisory services relating to medical problems; advisory services relating to medical services; medical screening; genetic testing for medical purposes; preparation of reports relating to medical matters for diagnostic or treatment purposes; provision of reports relating to the medical examination of individuals; performing diagnosis of diseases; providing medical information in the field of dermatology; genetic counseling; providing medical advice in the field of dermatology; pharmaceutical servicespreparation and dispensing of medications; analysis of human tissues for medical treatment
Publications
History of USPTO decisions and trademark events.
32 publications found
C71T
CANCELLED SECTION 71
11/21/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/26/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
05/07/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/25/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/25/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/25/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
11/19/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/13/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/26/2019
FIMP
FINAL DISPOSITION PROCESSED
08/26/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/07/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
05/07/2019
PUBO
PUBLISHED FOR OPPOSITION
02/19/2019
GPNX
NOTIFICATION PROCESSED BY IB
02/16/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/30/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/30/2019
NPUB
NOTICE OF PUBLICATION
01/30/2019
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
01/24/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/09/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/09/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/09/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/09/2019
RFNT
REFUSAL PROCESSED BY IB
07/27/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/12/2018
RFRR
REFUSAL PROCESSED BY MPU
07/12/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/03/2018
CNRT
NON-FINAL ACTION WRITTEN
07/02/2018
DOCK
ASSIGNED TO EXAMINER
06/20/2018
MAFR
APPLICATION FILING RECEIPT MAILED
06/19/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/15/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/14/2018
Continuous trademark protection
Get notified about every new filing that threatens MELAGENIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.